Myosana Therapeutics, Inc., a Seattle, WA-based new biotech company developing novel platform technology for non-viral gene delivery, raised up to $1M in seed financing.
CureDuchenne Ventures made the investment. As part of the transaction, Debra Miller, CEO and Founder of CureDuchenne, will join Myosana’s Board of Directors.
The company will use this initial funding to advance development of its innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD).
Founded in 2018 by University of Washington School of Medicine faculty members Nick Whitehead and Stan Froehner and led by Steve Runnels, Chief Executive Officer, Myosana Therapeutics has developed a non-viral gene delivery platform technology that specifically targets muscle cells to produce the missing protein caused by a mutation of a gene. The platform technology is applicable for both skeletal and cardiac muscles, and therefore an ideal therapy for Duchenne muscular dystrophy. Additionally, many other neuromuscular diseases may also benefit from this gene delivery approach, as it overcomes the many limitations of adeno-associated virus (AAV) gene therapy.